Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of Two Nimodipine Injections in Healthy Volunteers
NCT03794843Phase 1Unknown
- Sponsor
- Shenyang Dongxing Pharmaceutical Technology
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nimodipine in ischemic cerebrovascular disease (2 arms), sponsored by Shenyang Dongxing Pharmaceutical Technology. Primary endpoints: Area Under the Curve at 36 hours and Maximum Plasma Concentration at 36 hours. Status: unknown.
02
Drugs
nimodipine
03
Conditions
ischemic cerebrovascular disease
Beyond the preview
Go deeper on NCT03794843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794843.